RdRP-IN-9
RdRP-IN-9 (Compound 6b) is a reversible covalent allosteric inhibitor of RdRp. RdRP-IN-9 demonstrates high anti-coronavirus activity, with an EC50 value of 0.68 μM against HCoV-OC43 RdRP-IN-9 exerts a more prolonged antiviral effect by reversibly acylating Cys12 in the NiRAN domain of non-structural protein 12 (nsp 12) and exhibits synergistic anti-coronavirus activity with Molnupiravir (HY-135853) .
For research use only. We do not sell to patients.
- CAS No.: 1101848-34-3
- Formula: C19H21NO5
- Molecular Weight:343.37
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
EC50: 0.68 μM (HCoV-OC43)[1].
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MRC5 | IC50 |
4.99 μg/mL
Compound: 12
|
Cytotoxicity against human MRC5 cells after 7 days by MTT assay
Cytotoxicity against human MRC5 cells after 7 days by MTT assay
|
[PMID: 19013823] |
Chemical Information
-
CAS No. 1101848-34-3
-
Molecular Weight 343.37
-
Formula C19H21NO5
-
SMILES
[H][C@@]12[C@](C3=C[C@H](O)[C@H]2OC(CC)=O)([H])N(CC3)CC4=CC5=C(OCO5)C=C41
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
RdRP-IN-9 Related Classifications
HY-170649 Related Classifications
Powered by Bioz